COLO B Coloplast A/S Class B

Coloplast A/S - Q1 2024/25 Earnings Release - Invitation to conference call on 4 February 2025 at 11.00am CET

Coloplast A/S - Q1 2024/25 Earnings Release - Invitation to conference call on 4 February 2025 at 11.00am CET

Tuesday, 4 February 2025 at 10.00 - 11.00am CET

In connection with the publication of Coloplast’s interim financial results for Q1 2024/25, to be released same day around 07.30am CET, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast’s website approximately 1 hour before the conference call.

The webcast of the conference call will be available during and after the event.



Coloplast will be represented by:

Kristian Villumsen - President & CEO

Anders Lonning-Skovgaard - Executive Vice President, CFO

Aleksandra Dimovska - Vice President, Investor Relations

Simone Dyrby Helvind - Senior Manager, Investor Relations



Webcast

For participants who do not wish to actively participate in the Q&A session, please access the conference call as a webcast via the link below:



Dial-in details

To actively participate in the Q&A session, please sign up ahead of the conference call on the link below to receive an email with dial-in details.

 

For more information, please contact:

Aleksandra Dimovska - Vice President, Investor Relations

Tel.: / direct: . E-mail:

Simone Dyrby Helvind - Senior Manager, Investor Relations

Tel.: / direct: . E-mail: 

Julie Isabella Sommer Müggler - Coordinator & PA, Investor Relations

Tel.: / direct: . E-mail: 

 

Coloplast will be available on individual phone lines after the conference call for further questions.

Attachment



EN
21/01/2025

Underlying

COLO BColoplast A/S Class B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coloplast A/S Class B

 PRESS RELEASE
Free
COLO B Coloplast A/S C...

Coloplast A/S - Q1 2024/25 Earnings Release - Invitation to conference...

Coloplast A/S - Q1 2024/25 Earnings Release - Invitation to conference call on 4 February 2025 at 11.00am CET (correction) Tuesday, 4 February 2025 at 11.00 - 12.00am CET (corrected from 10.00 - 11.00am CET in an earlier version of this invitation)In connection with the publication of Coloplast’s interim financial results for Q1 2024/25, to be released same day around 07.30am CET, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast’s website approximately 1 hour befor...

4h / 2m 1 EN
 PRESS RELEASE
Free
COLO B Coloplast A/S C...

Coloplast A/S - Q1 2024/25 Earnings Release - Invitation to conference...

Coloplast A/S - Q1 2024/25 Earnings Release - Invitation to conference call on 4 February 2025 at 11.00am CET Tuesday, 4 February 2025 at 10.00 - 11.00am CETIn connection with the publication of Coloplast’s interim financial results for Q1 2024/25, to be released same day around 07.30am CET, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast’s website approximately 1 hour before the conference call.The webcast of the conference call will be available during and afte...

23h / 26m 1 EN
Rune Majlund Dahl
  • Rune Majlund Dahl
Free Trial
COLO B Coloplast A/S C...

Coloplast (Hold, TP: DKK850.00) - Q1 likely below full-year guidance

We forecast Q1 results below the full-year guidance, with organic growth of 7.5% and an EBIT before special items margin of 27.0%, but expect improvements in subsequent quarters. We look for unchanged guidance of 8–9% organic growth and a c28% EBIT margin before special items. We believe returning to 30%+ EBIT margins hinges on external factors. We reiterate our HOLD but have cut our target price to DKK850 (930).

COLO B COLOPLAST A/S CLASS B
01/16/25 January 16, 2025 1 EN
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
COLO B COLOPLAST A/S CLASS B
01/13/25 January 13, 2025 1 EN
Free Trial
COLO B Coloplast A/S C...

Coloplast AS: 1 director

A director at Coloplast AS bought 23,700 shares at 845.850DKK and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...

COLO B COLOPLAST A/S CLASS B
12/11/24 December 11, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch